

**PRESS RELEASE**  
**FOR IMMEDIATE RELEASE**

**PHARMANIAGA COMPLETES 10% PRIVATE SHARE  
PLACEMENT, MAJOR SHAREHOLDER LTAT COMMITS  
ANOTHER 10%, REFLECTING STRONG FUNDAMENTALS  
OF THE BUSINESS**

**SHAH ALAM, 21 July 2023** – Pharmaniaga Berhad (Pharmaniaga) today has successfully completed its 10% first private share placement exercise and a second tranche of 10% is expected to be taken up by Armed Forces Fund Board (LTAT), subject to shareholders' approval.

The first private share placement, announced on 13 July 2023 saw the issuance of 131,020,866 new ordinary shares to third-party investors which is aligned with the general mandate granted during Pharmaniaga's 25th Annual General Meeting held on 12 June 2023, authorising the Board to issue up to 10% of the Group's issued shares.

The success of the private share placement exercise shows the investors' confidence in Pharmaniaga's growth trajectory and strategic direction, signalling potential enhancement to the Group's financial stability. These investors that took up the first private placement share were both from institutions and individuals.

Meanwhile, LTAT's strategic move will potentially secure up to 10% extra placement shares, with the issue price to be determined at a later date. This new placement is set to allow the Group to raise additional funds, supplementing the proceeds to be received from the first private share placement.

These interim measures will support the Group's working capital requirements while a full Regularisation Plan is being formulated. The main objective of this strategic move is to strengthen Pharmaniaga's financial standing, hence enabling the Group to reduce debt and improve cashflow.

The Group appreciates the continuous support from its shareholders and is enthusiastic about its potential. Our steadfast dedication is towards fostering sustained growth and consistently enhancing the share value for our loyal shareholders.

**-END-**

**About Pharmaniaga Berhad**

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy. With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena. For more information, please log on to <https://pharmaniaga.com/>

**Issued for Pharmaniaga Group by Corporate Communication Division, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman at 03- 3342 9999 ext 434 or email [zuhri@pharmaniaga.com](mailto:zuhri@pharmaniaga.com) .**